MarginsXMarginsX
Home › Markets › Health Care › PMVP

PMV Pharmaceuticals Inc. (PMVP)

PMVP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.19
-6.30% on the day
Market cap
$89.9M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerPMVP on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001699382
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
3.4 months
$20.0M cash at September 30, 2026
Share count, 1 year
+42.0%
2025-11-12 to 2026-11-10 · +47.7% over 3 years
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
-$1.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"As a result, management has concluded that there is no longer substantial doubt about the Company's ability to continue as a going concern as of the date of this Quarterly Report."
10-Q 2026-11-10
Cash and burn$20.0M cash; operating cash flow -$17.4M a quarter.Report 2026-09-30
Shares outstanding75,534,742 (2026-11-10); 53,211,507 a year earlier; 51,157,636 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-09-02
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-17
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$34.4M-$18.2M$20.0MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$18.1M-$14.6M$12.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$18.0M-$19.7M$39.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$18.0M-$17.2M$38.0MNo debt tagsNeeds four quarters10-K 2026-03-06
Q3 2025
2025-09-30
Not filed-$21.1M-$19.8M$36.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$21.2M-$18.3M$44.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$17.4M-$18.3M$51.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$23.0M-$16.7M$40.9MNo debt tagsNeeds four quarters10-K 2026-03-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-09-02
Latest annual report10-K2026-03-06
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 393 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.8%
1 month-5.9%
3 months+4.5%
Year to date+1.6%
1 year-6.6%
From 52-week high-29.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
NBPNovaBridge Biosciences$0.7915-6.87%$91.3M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
GNLXGenelux Corporation$1.92+2.95%$86.9M
NKTXNkarta Inc.$1.21+1.68%$86.8M
RLYBRallybio Corporation$15.43-1.88%$86.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier